MD・アンダーソン研究者は TMSを開発し 3つの陰性乳がんの化学反応を より正確に予測し 腫瘍遺伝子の活動を分析し MD Anderson researchers created TmS, a new biomarker that better predicts chemo response in triple-negative breast cancer by analyzing tumor gene activity and microenvironment, showing promise for personalized treatment.

MD アンダーソンガンセンターの研究者は,TMSの新たなバイオマーカーを開発し,ガンの遺伝子表現の変化と腫瘍の微細な変化を考慮して,三重陰性乳がんに対する化学療法の反応の予測を改善した. Researchers at MD Anderson Cancer Center have developed a new biomarker, TmS, which improves predictions of chemotherapy response in triple-negative breast cancer by accounting for gene expression changes within tumors and their microenvironments. 575の民族的多様な患者を検定し,TMSは高血圧と低血圧のグループを区別して既存のモデルを除外し,欧米とアジアの患者の腫瘍の微細化の違いを明らかにし,個性的治療の潜在性を示唆した. Tested on 575 ethnically diverse patients, TmS outperformed existing models in distinguishing high- and low-prognosis groups and revealed differences in tumor microenvironments between Western and Asian patients, suggesting potential for personalized treatments. このツールは腫瘍細胞比とRNA活動ダイナミクスを統合し,より正確でアクセス可能な患者の層分化の方法を提供していますが,臨床使用前にさらなる検証が必要です. The tool integrates tumor cell ratios and RNA activity dynamics, offering a more accurate, accessible method for patient stratification, though further validation is needed before clinical use.